Technology
Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent
Revenues from pharmaceutical products were almost entirely driven by the COVID-19 treatment remdesivir, though sales of Kite Pharma's CAR T-cell therapies grew, too.
Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer
Premium
MHC-II expression could be useful for guiding neoadjuvant immunotherapy in HER2-negative breast cancers, according to findings in Clinical Cancer Research.
Genomes of Advanced Neuroendocrine Neoplasms Unveil Subtypes, Treatment Clues
By sequencing dozens of locally advanced or metastatic neuroendocrine neoplasm samples, researchers detected somatic mutations that varied with primary tumor site and subtype.
Bristol Myers Squibb Q2 Revenues Grow 16 Percent
The firm's checkpoint inhibitor Opdivo returned to growth in the quarter with sales of $1.91 billion, an increase of 16 percent compared to Q2 2020.
The digital pathology firm is working to further develop its diagnostic capabilities and broaden its menu of algorithms for different diseases.